Tuesday, May 31, 2011

UCB,s new data for Cimzia® (certolizumab pegol) showed a rapid clinical response across a broad population of RA patients

UCB, announced data which showed that the addition of Cimzia® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. Company also claims that, consistent efficacy was observed across patients taking certolizumab pegol whether they had previously received TNF inhibitors or not and whether they received certolizumab pegol monotherapy or with concomitant DMARDs.....

No comments:

Post a Comment